GlassScriptPhysician profile
Scott L Huang
NPI 1225186257
$22,349.96
in general payments reported to CMS, 2019-2025
43 companies · $3,990 in 2025
The $3,990 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,495 · 2020: $1,263 · 2021: $1,923 · 2022: $2,955 · 2023: $3,710 · 2024: $5,013 · 2025: $3,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,713.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $3,130.00 | 2019-2025 | Vemlidy, Yeztugo |
| Amgen INC. | $2,361.38 | 2019-2025 | Tavneos, Evenity, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $2,201.89 | 2019-2025 | Farxiga, Lokelma, Airsupra |
| Glaxosmithkline, LLC. | $1,633.34 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $1,483.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $1,223.68 | 2022-2025 | |
| Lilly USA, LLC | $1,050.52 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Viiv Healthcare Company | $1,012.90 | 2022-2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $945.45 | 2019-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $820.45 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $724.55 | 2019-2024 | Reblozyl, Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $589.19 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $506.26 | 2019-2024 | Xifaxan |
| Scilex Pharmaceuticals INC. | $449.36 | 2022-2025 | Ztlido |
| Dynavax Technologies Corporation | $389.29 | 2019-2025 | Heplisav-B |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $372.78 | 2020-2023 | |
| Calliditas Therapeutics US INC. | $318.23 | 2023-2025 | Tarpeyo |
| Mallinckrodt Hospital Products INC. | $313.41 | 2023-2025 | Acthar |
| Shire North American Group INC | $259.32 | 2019 | |
| Agios Pharmaceuticals, INC. | $256.62 | 2024-2025 | Pyrukynd |
| Horizon Therapeutics Plc | $235.96 | 2022-2023 | Krystexxa |
| Stryker Corporation | $173.45 | 2024 | Omnicurve |
| Viatris Specialty LLC | $151.13 | 2025 | Yupelri |
| Cequr Corporation | $148.28 | 2023 | Cequr Simplicity |
| Astellas Pharma US INC | $145.19 | 2019-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $136.90 | 2024 | Austedo Xr |
| Amarin Pharma, INC. | $128.50 | 2019 | |
| Mirum Pharmaceuticals, INC. | $122.69 | 2025 | Livmarli |
| Eisai INC. | $118.73 | 2025 | |
| Lexicon Pharmaceuticals, INC. | $113.96 | 2024 | Inpefa |
| Abbvie INC. | $112.66 | 2019 | |
| Janssen Biotech, INC. | $110.32 | 2022 | |
| Xeris Pharmaceuticals, INC. | $103.09 | 2023-2024 | Gvoke Hypopen |
| Edwards Lifesciences Corporation | $88.17 | 2024 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $78.29 | 2023-2025 | Cologuard Collection Kit |
| Vifor Pharma, INC. | $74.52 | 2019-2024 | Veltassa |
| Dexcom, INC. | $72.10 | 2024-2025 | Dexcom G6 Transmitter |
| Travere Therapeutics, INC. | $63.55 | 2025 | |
| Mannkind Corporation | $50.23 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.33 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.26 | 2023 | Jynarque |
| Ultragenyx Pharmaceutical INC. | $18.22 | 2021 | |
| Modernatx, INC. | $16.98 | 2025 | Mresvia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.